European growth debt fund Claret Capital Partners raises €575M, with a third earmarked for biotech, medtech and diagnostics ...
After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months.
Zymeworks is set to put Theravance Biopharma out of its misery, announcing on Monday that it will buy the biotech for $929 million upfront in cash. In March, Theravance said it was ...
Lindus Therapeutics sheds its CRO business, rebrands from Lindus Health and pivots to in-licensing external drug assets, CEO ...
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust ...
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future ...
Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results